## Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: L10I • G16E • M36I • N37K • R41K • R57RK • Q61E • I62IM • L63T • H69K • L89M • I93L

| Protease Inhibitors | |
|---|---|
| **atazanavir/r (ATV/r)** | Susceptible |
| **darunavir/r (DRV/r)** | Susceptible |
| **fosamprenavir/r (FPV/r)** | Susceptible |
| **indinavir/r (IDV/r)** | Susceptible |
| **lopinavir/r (LPV/r)** | Susceptible |
| **nelfinavir (NFV)** | Susceptible |
| **saquinavir/r (SQV/r)** | Susceptible |
| **tipranavir/r (TPV/r)** | Susceptible |

**PR comments**

**Other**

- **L10I/V** are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

## Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for PI.*

## Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: M184V
NNRTI Mutations: P225PH
RT Other Mutations: P4PS • V35T • E36EV • T39E • K122KE • I135L • I142IV • K173AT • Q174K • D177E • I178IM • T200A • Q207E • R211Q • V245Q • A272P • K275KQ • K277KR • T286A • E291D • V292I • I293V • V317A • I329IV • A554S

| Nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **abacavir (ABC)** | Low-Level Resistance |
| **zidovudine (AZT)** | Susceptible |
| **stavudine (D4T)** | Susceptible |
| **didanosine (DDI)** | Potential Low-Level Resistance |
| **emtricitabine (FTC)** | High-Level Resistance |
| **lamivudine (3TC)** | High-Level Resistance |
| **tenofovir (TDF)** | Susceptible |

| Non-nucleoside Reverse Transcriptase Inhibitors | |
|---|---|
| **doravirine (DOR)** | Low-Level Resistance |
| **efavirenz (EFV)** | Intermediate Resistance |
| **etravirine (ETR)** | Susceptible |
| **nevirapine (NVP)** | Intermediate Resistance |
| **rilpivirine (RPV)** | Susceptible |

**RT comments**

**NRTI**

- **M184V/I** cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). **M184V/I** are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

**NNRTI**

- **P225H** is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of **P225H** and K103N synergistically reduces NVP, EFV and DOR susceptibility.

## Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

*Drug resistance mutation scores of NRTI:* Download CSV

| Rule | ABC | AZT | D4T | DDI | FTC | 3TC | TDF |
|---|---|---|---|---|---|---|---|
| M184V | 15 | -10 | -10 | 10 | 60 | 60 | -10 |

*Drug resistance mutation scores of NNRTI:* Download CSV

| Rule | DOR | EFV | ETR | NVP | RPV |
|---|---|---|---|---|---|
| P225PH | 20 | 45 | 0 | 45 | 0 |

## Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: None
IN Other Mutations: S17N • D25E • V31I • G59E • I84M • L101I • T112V • T124N • D167E • K173R • V201I • L234I • S255G

| Integrase Strand Transfer Inhibitors | |
|---|---|
| **bictegravir (BIC)** | Susceptible |
| **cabotegravir (CAB)** | Susceptible |
| **dolutegravir (DTG)** | Susceptible |
| **elvitegravir (EVG)** | Susceptible |
| **raltegravir (RAL)** | Susceptible |

Mutation scoring: IN HIVDB 9.5.1 (2023-11-05)

*No drug resistance mutations were found for INSTI.*